摘要
为了观察多亚型α干扰素与2b型α干扰素治疗慢性乙型肝炎近远期疗效的差异。随机选60例慢性乙型肝炎分成A、B两组分别接受IFN—αNI和IFN—α2b治疗。给药方法相同,3MU×22周,后为3MU×22周。在12周时A组和B组ALT复常率分别为66.7％和60.0％(P>0.05)、HBeAg阴转率为53.3％和43.3％(P>0.05)、HBV—DNA阴转率为50.0％和40.0％(P>0.05)。24周时ALT复常率为83.3％和66.7％(P<0.05)、HBeAg阴转率为60.0％和33.3％(P<0.05)、HBV—DNA阴转率为56.7％和30.0％(P<0.05)。72周时ALT复常率为90.0％和53.3％(P<0.05)、HBeAg阴转率为66.7％和26.7％(P<0.005)、HBV—DNA阴转率为63.3％和26.7％(P<0.005)。以上结果说明IFN—αNI治疗慢性乙型肝炎近远期疗效明显优于IFN—α2b,这种差异可能来源于干扰素的多亚型。
In order to comparethe short-term and long-term efficacy of IFN-α N1 with IFN-α2b ina 24-week-treatment for CHB. 60 patients with CHB were randomly divided into group A and group B. Patients in group A were received IFN-αN1, whilepatients in group B were received IFN-α 2b. All patients in two group werereceived IFN-αat the same dosing regimen,once a day for two weeks,then three times weekly for 22 weeks. At 12 weeks,the rate of ALT returning to normal was 66. 7% and 60. 0%( P >0. 05),the negative serconversation rate of HBeAg was 53. 3% and 43. 3% ( P <0. 05) ,of HBV-DNA was 56. 7% and 30. 0%( P <0. 05),At 72 weeks,the rate ofALT retuning to normal was 90.0% and 53. 3%( P >0. 05),negative serconversation rate of HBeAg was 66. 7% and 26. 7%( P <0. 005),of HBV-DNA was 56. 7% and 30. 0) P <0. 05 ).At 72 weeks,the rate ofALT retuning to normal was 90. 0% and 53. 3% P <0. 05),negative serconversation rate of HBeAg was 66. 7% and 26. 7%( P <0. 005),of HBV-DNA was 63. 3% and 26. 7%( P <0. 005),the results suggested theshort-term and long-term efficacy of IFN-αNl was superior to that of IFN -α2b,this difference resulted from the diversity ofα-IFN subtype.
出处
《医学理论与实践》
1999年第9期503-505,共3页
The Journal of Medical Theory and Practice
